Serina Therapeutics Company Insiders
| SER Stock | 5.22 0.43 8.98% |
Serina Therapeutics employs about 9 people. The company is managed by 7 executives with a total tenure of roughly 21 years, averaging almost 3.0 years of service per executive, having 1.29 employees per reported executive. Discussion of Serina Therapeutics' management performance can provide insight into the enterprise performance.
Serina |
Serina Therapeutics Management Team Effectiveness
The company has Return on Asset of (0.4529) % which means that on every $100 spent on assets, it lost $0.4529. This is way below average. Serina Therapeutics' management efficiency ratios could be used to measure how well Serina Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/18/2024, Return On Tangible Assets is likely to drop to -1.37. In addition to that, Return On Capital Employed is likely to grow to -1.56. At this time, Serina Therapeutics' Total Assets are relatively stable compared to the past year. As of 12/18/2024, Non Current Assets Total is likely to grow to about 11.8 M, while Return On Tangible Assets are likely to drop (1.37).As of 12/18/2024, Common Stock Shares Outstanding is likely to grow to about 1.2 M
Serina Therapeutics Workforce Comparison
Serina Therapeutics is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 58,452. Serina Therapeutics adds roughly 9.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Net Profit Margin of (2.21) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (75.8) %, which entails that for every $100 of revenue, it lost $75.8. Serina Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Serina Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Serina Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Serina Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Serina Therapeutics Notable Stakeholders
A Serina Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Serina Therapeutics often face trade-offs trying to please all of them. Serina Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Serina Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Bentley | Chief CoFounder | Profile | |
| Milton Harris | CoFounder Board | Profile | |
| Balkrishan Gill | Executive Chairman | Profile | |
| Steven Ledger | Interim Director | Profile | |
| EunJae CPA | Interim Officer | Profile | |
| Tacey Viegas | Chief Officer | Profile | |
| Srini Tenjarla | Manufacturing Chemistry | Profile |
About Serina Therapeutics Management Performance
The success or failure of an entity such as Serina Therapeutics often depends on how effective the management is. Serina Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Serina management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Serina management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.30) | (1.37) | |
| Return On Capital Employed | (1.65) | (1.56) | |
| Return On Assets | (1.24) | (1.30) | |
| Return On Equity | (2.71) | (2.57) |
Serina Therapeutics Workforce Analysis
Traditionally, organizations such as Serina Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Serina Therapeutics within its industry.Serina Therapeutics Manpower Efficiency
Return on Serina Therapeutics Manpower
| Revenue Per Employee | 15.8K | |
| Revenue Per Executive | 20.3K | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 2.1M | |
| Working Capital Per Employee | 12.3K | |
| Working Capital Per Executive | 15.8K |
Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.